Skip to content

Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates

Asymptomatic Carotid Stenosis: Cognitive Function and Plaque Correlates

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01353196
Acronym
ACCOF
Enrollment
170
Registered
2011-05-12
Start date
2011-05-15
Completion date
2018-02-28
Last updated
2019-07-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Manifestations

Keywords

carotid, atherosclerosis, cognitive function

Brief summary

Carotid artery plaques are known to cause stroke. Cognitive impairment is an insidious but poorly understood problem in patients with carotid plaques. Cognitive function describes how people perform mental processes such as thinking, learning and problem solving. Asymptomatic carotid plaques may affect 1 million Veterans who may be at risk for cognitive impairment. In this study, the investigators will uncover the extent of cognitive impairment in Veterans with carotid stenosis who are currently labeled asymptomatic. Programs to prevent or mitigate cognitive impairment will depend on identifying the mechanisms by which this occurs. The investigators will use sophisticated 3D imaging techniques developed by the group to measure the structure and composition of plaques, number of particles breaking off from them, blood levels of chemicals that could disrupt them, and blood flow restriction to the brain from them. This will help identify patients at risk for cognitive impairment who may benefit from preventative measures and improve selection of patients to decrease unnecessary surgical procedures.

Detailed description

Carotid artery stenosis is a well-known cause of atheroembolic stroke. Stroke prevention in these patients has been the focus of intense investigation. Cognitive impairment is a more insidious but poorly understood outcome in patients with asymptomatic carotid stenosis who have not suffered a stroke. Cognitive function describes how a person produces and controls mental processes such as thinking, learning, and problem solving. It is an important outcome measure that affects patient well-being and their ability to live independent productive lies. It is well-known that cognitive impairment coexists in patients with stroke from carotid stenosis. However, isolated cognitive deficits in patients with asymptomatic carotid stenosis have not been looked for, and have therefore not been reported in any detail. Asymptomatic carotid stenosis affects 2-12% of people. With 23.4 million Veterans in the country, at least 1 million (4.3%) have asymptomatic carotid stenosis and are at risk for cognitive impairment. A subset analysis of the Cardiovascular Health Study found cognitive decline in 34% of 32 patients with asymptomatic carotid stenosis. In this proposal, the investigators will define the extent of initial and progressive cognitive impairment in Veterans with carotid stenosis who are currently labeled as asymptomatic in the absence of a focal neurologic deficit (stroke, transient ischemic attack). Programs to prevent, postpone, or mitigate cognitive impairment in patients with carotid stenosis will depend on the identification of mediators for cognitive impairment. Microembolic brain injury and cerebral hypoperfusion have been associated with cognitive impairment in elderly individuals. Therefore plaque architecture, plaque composition, microembolic counts, serum inflammatory markers, and cerebral hypoperfusion are likely mediators of impaired cognition in patients with asymptomatic carotid stenosis. As part of this proposal, the investigators will identify the biological mechanisms by which carotid stenosis could result in cognitive impairment. The goal of this proposal is to perform a systematic, adequately powered study to measure the magnitude of cognitive impairment in asymptomatic carotid stenosis, its impact on quality of life, and its potential pathophysiological mechanisms. Information from this study will define an unsuspected morbidity of carotid stenosis and identify subsets of patients at risk for cognitive impairment. It will form the foundation for future studies on prevention, pre-emptive treatment, or rehabilitation of patients with carotid stenosis. It will also improve the selection of patients with carotid stenosis to decrease unnecessary revascularization procedures. Specific Aim 1 will assess if patients with asymptomatic carotid stenosis differ in cognitive function compared to age-matched controls without carotid stenosis but with similar vascular risk profiles. The investigators hypothesize that in patients with asymptomatic carotid stenosis 50% who survive stroke free for 2 years; the change in overall and domain-specific cognitive function will be significantly different compared to those without stenosis. The study will recruit 284 subjects and will detect a clinically significant difference in cognitive score with 90% power. The investigators will use a novel battery of cognitive tests specifically developed to address the unique issues relating to carotid stenosis. Specific Aim 2 will define plaque-morphometric, biologic, and hemodynamic characteristics that correlate with cognitive impairment in patients with asymptomatic carotid stenosis. The investigators hypothesize that carotid plaque architecture, plaque composition, microembolic counts, serum pro-inflammatory markers, and cerebral hypoperfusion could each mediate cognitive decline over a 2-year follow-up period. The investigators will implement a novel clinical 3D B-mode ultrasound imaging technique developed to obtain reliable serial plaque measurements. Specific Aim 3 will measure the impact of cognitive impairment on quality of life. The investigators hypothesize that at 2 years, regardless of plaque features, cognitive impairment will correlate with a reduction in health-related quality of life measures.

Interventions

None listed

Sponsors

VA Office of Research and Development
Lead SponsorFED

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* asymptomatic 50% carotid stenosis or more

Exclusion criteria

* previous stroke or transient ischemic attack (TIA) * severe medical illness that would interfere with evaluation of outcomes or reduce the likelihood of a 2-year follow-up * carotid occlusion * patients scheduled for carotid revascularization procedures

Design outcomes

Primary

MeasureTime frameDescription
Composite Cognitive Score2 yearscomposite of multiple cognitive function test scores scores are reported as mean +/- standard deviation 0 = worst 100 = best

Countries

United States

Participant flow

Participants by arm

ArmCount
Stenosis
carotid stenosis
100
no Stenosis
no carotid artery stenosis
70
Total170

Baseline characteristics

CharacteristicStenosisno StenosisTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
74 Participants44 Participants118 Participants
Age, Categorical
Between 18 and 65 years
26 Participants26 Participants52 Participants
Age, Continuous50 years
STANDARD_DEVIATION 10
50 years
STANDARD_DEVIATION 10
50 years
STANDARD_DEVIATION 10
Composite cognitive function45.5 units on a scale
STANDARD_DEVIATION 6
47.9 units on a scale
STANDARD_DEVIATION 5
46.0 units on a scale
STANDARD_DEVIATION 5.5
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
24 Participants34 Participants58 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
76 Participants36 Participants112 Participants
Sex: Female, Male
Female
1 Participants2 Participants3 Participants
Sex: Female, Male
Male
99 Participants68 Participants167 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
18 / 10011 / 70
other
Total, other adverse events
0 / 1000 / 70
serious
Total, serious adverse events
0 / 1000 / 70

Outcome results

Primary

Composite Cognitive Score

composite of multiple cognitive function test scores scores are reported as mean +/- standard deviation 0 = worst 100 = best

Time frame: 2 years

Population: Participants that did not complete the study or missing key data elements were excluded from the overall analysis

ArmMeasureValue (MEAN)Dispersion
StenosisComposite Cognitive Score45.5 units on a scaleStandard Deviation 6
no StenosisComposite Cognitive Score47.9 units on a scaleStandard Deviation 5

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026